2026
March
LNP mRNA delivery gets a metabolic boost from amino acid supplement
March 25, 2026
Lipid nanoparticles (LNPs) have allowed for the delivery of therapeutic mRNA for various therapeutic applications. However, in vivo delivery efficacy is often limited, and research is focused on optimization of LNP formulations. In recent work published in Science Translational Medicine, Chen, Wang, et al. assessed how the in vivo metabolic state impacts LNP...
The surprising effect of TOX in CD4+ T cells
March 18, 2026
In settings of chronic antigen stimulation, such as chronic infection and cancer, expression of the transcription factor TOX in CD8+ T cells has been associated with cell persistence and survival, but also with exhaustion, dysfunction, and poor prognosis. As the role of TOX in CD4+ T cells is less well understood, Naizir et...
Neoantigen vaccination boosts long-lasting T cell responses in TNBC
March 11, 2026
Triple-negative breast cancer (TNBC) is characterized by DNA repair deficiency, genomic instability, and an immunogenic tumor microenvironment, suggesting it might serve as a candidate for individualized vaccination targeting somatic tumor mutation-associated neoantigens. Sahin, Schmidt, et al. recently published the results of a first-in-human clinical study with this strategy in Nature. To develop the...
AACR IO 2026
March 4, 2026
The ACIR team attended the AACR IO meeting held on February 18-21, 2026 in Los Angeles, CA, USA. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. T cellsPhilip D. GreenbergRafi AhmedFred RamsdellAlexander MarsonRobert G. NewmanOwen N. Witte Checkpoint blockadeFathia Mami-ChouaiDario A. VignaliMegan...
